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Association Between Homocysteine and Vascular Calcification
Incidence, Prevalence, and Progression in the MESA Cohort
Amy B. Karger, MD, PhD; Brian T. Steffen, PhD; Sarah O. Nomura, PhD; Weihua Guan, PhD; Parveen K. Garg, MD, MPH; Moyses Szklo, MD,
MPH; Matthew J. Budoff, MD; Michael Y. Tsai, PhD
Background-—While elevated homocysteine has been associated with calcification in several studies, its importance as a
cardiovascular risk factor remains unclear. This study examines the relationship between homocysteine and vascular and valve
calcification in the MESA (Multi-ethnic Study of Atherosclerosis) cohort.
Methods and Results-—MESA participants with baseline homocysteine measurements and cardiac computed tomography scans
were included (N=6789). Baseline and follow-up assessment of vascular (coronary artery [CAC], descending thoracic aorta [DTAC])
and valve (aortic valve [AVC], mitral annular [MAC]) calcification was performed. Prevalence ratio/relative risk regression was used
to assess the relationship of homocysteine with prevalent and incident calcification, and multivariable logistic regression was used
to assess associations between homocysteine and calcification progression. Elevated homocysteine was associated with greater
relative risk of prevalent and incident CAC and incident DTAC. We also identified a strong association between elevated
homocysteine and CAC and DTAC progression. Elevated homocysteine was found to confer a >2-fold increased risk of severe CAC
progression (defined as DCAC ≥100/year) and an 1.5-fold increased risk for severe DTAC progression (defined as DDTAC ≥100/
year).
Conclusions-—To our knowledge, this is the first study demonstrating an association between elevated homocysteine and both
incidence and progression of coronary and extra-coronary vascular calcification. Our findings suggest a potential role for elevated
homocysteine as a risk factor for severe vascular calcification progression. Future studies are warranted to further assess the
utility of homocysteine as a biomarker for vascular calcification incidence and progression.
Clinical Trial Registration-—https://www.clinicaltrials.gov/. Unique identifier: NCT00005487. ( J Am Heart Assoc. 2020;9:
e013934. DOI: 10.1161/JAHA.119.013934.)
Key Words: calcification progression • cardiovascular disease • homocysteine • vascular calcification
E levated plasma homocysteine (Hcy) was first proposedas a cause of vascular pathology in patients with
inherited disorders of homocysteine metabolism,1 leading to
the hypothesis that individuals with mild to moderately
elevated homocysteine levels may have an increased risk
for vascular disease. As an amino acid with a reactive
sulfhydryl group, homocysteine has been proposed to mediate
vascular inflammation and damage by promoting oxidative
stress secondary to reactive oxygen species accumulation,2
which in turn leads to an increase in cardiac and vascular
disease risk by promoting endothelial dysfunction, smooth
muscle cell proliferation, and vascular calcification.2,3 Con-
sistent with this hypothesis, hyperhomocysteinemia has been
associated with an increased risk for coronary heart disease
(CHD), heart failure, atrial fibrillation, stroke, and mortality.4–9
However, the importance of homocysteine as a risk factor
for heart disease remains uncertain. A recent meta-analysis
concluded that methylene tetrahydrofolate reductase gene
(MTHFR) variants associated with moderate hyperhomocys-
teinemia have little to no effect on CHD when unpublished
data sets are analyzed, suggesting publication bias.10 An
additional meta-analysis found that folic acid supplementa-
tion, which lowers homocysteine levels, had little to no effect
on CHD risk.11 Despite this evidence, studies have demon-
strated clear associations between elevated homocysteine
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and calcification,3,12,13 and vascular and valvular calcification
are well-established risk factors for cardiovascular morbidity
and mortality.14–16
Given the controversy about the role of homocysteine as a
risk factor for development of CHD, we were interested in
assessing the potential role of homocysteine in vascular
disease. The objective of this study was to determine
whether elevated homocysteine is associated with valvular
and/or vascular calcification among participants in the MESA
cohort.
Methods
Study Population
The objectives and design of MESA (Multi-Ethnic Study of
Atherosclerosis) have been previously described.17 Briefly,
MESA is a prospective study involving 6814 men and women
aged 45 to 85 years at baseline (2000–2002), from 4 racial/
ethnic groups (white, black, Hispanic, and Chinese). Subjects
were recruited from 6 field centers in the United States and
were free of known cardiovascular disease at the time of
recruitment. The primary purpose of MESA is to study the
development and progression of subclinical cardiovascular
disease. Our study population included all MESA participants
with baseline homocysteine measurements and baseline
cardiac computerized tomography (CT) scans (n=6789). Study
participants gave informed consent, and institutional review
board approval was given at all MESA sites. The data, analytic
methods, and study materials will not be made available to
other researchers for purposes of reproducing the results or
replicating the procedure.
Laboratory Measurement of Plasma
Homocysteine and Other Blood Biomarkers
Plasma homocysteine was measured with high performance
liquid chromatography, using fluorometric detection. The
assay’s coefficient of variation (CV) was 3.8%. Total cholesterol
was measured in EDTA plasma with the cholesterol oxidase
method on the Roche COBAS analyzer (Roche Diagnostics) at
the University of Minnesota Advanced Research and Diagnostic
Laboratory, with an assay CV of 1.6%. High-density lipoprotein
(HDL) cholesterol was measured by the same method after
precipitation of non-HDL cholesterol with magnesium/dextran,
with an assay CV of 2.9%. CRP (C-reactive protein) was
measured with a BNII nephelometer (Dade Behring Inc) at the
Laboratory for Clinical Biochemistry Research at the University
of Vermont with an assay CV of 3.6%.
CT Imaging for Assessment of Arterial and
Valvular Calcification
Quantitation of coronary artery calcification (CAC), descending
thoracic aorta calcification (DTAC), aortic valve calcification
(AVC) and mitral annular calcification (MAC) have been
described previously, and all were assessed using cardiac
computed tomography (CT) with the Agatston scoring
method.18,19 Ascending thoracic aorta calcification (ATAC)
was not included in the analysis because of the low prevalence
in the MESA cohort.20 All cardiac CT scans were read at the
MESA central reading center (Los Angeles Biomedical Research
Institute, at Harbor-UCLA, Torrance, California).
Cardiac CT scans were performed at baseline and follow-up
visits on participants. Specifically, the first follow-up scanswere
performed at visit 2 (n=2914) or visit 3 (n=2925),21 occurring an
average of 2.5 years after baseline scans, with CAC, DTAC,
AVC, andMAC assessed. A prior study assessing risk factors for
CAC in MESA characterized the individuals with missing follow-
up cardiac CT scans, and found that they were slightly older,
more likely to have CAC at baseline, had higher systolic blood
pressure, increased prevalence of diabetes mellitus, and more
likely to be a current smoker.22 Visit 4 scans for CAC were
assessed in a subset of participants (n=1349), preferentially
targeting those that had missed a visit 3 scan.21 At visit 5, an
average of 10 years after baseline scans, CACwasmeasured an
additional time in participants (n=3304).21
Measurement of Other Covariates
Standardized questionnaires were used to collect demo-
graphic and medication use history, including age, sex,
education, hypertension medication use, lipid lowering med-
ication use, smoking status, and alcohol use.17 Body mass
index parameters (weight and height) and blood pressure
were measured by trained clinical site staff, and cholesterol
Clinical Perspective
What Is New?
• This is the first study showing an association between
elevated homocysteine and both incidence and progression
of coronary and extra-coronary vascular calcification.
• This study challenges prior research which has questioned
homocysteine’s role as a cardiovascular disease risk factor
because of lack of impact of homocysteine-lowering ther-
apies, which were administered for short time frames that
may have been inadequate to halt or reverse effects of long-
term homocysteine elevation.
What Are the Clinical Implications?
• Homocysteine may have a role in predicting risk for
incidence and progression of vascular calcification.
• Further studies are needed to ascertain the role of
homocysteine as a marker and risk factor for atheroscle-
rosis and cardiovascular disease.
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and HDL-C measurements were performed on blood samples
collected from participants.17 Diabetes mellitus status was
defined as a fasting glucose of ≥126 mg/dL, self-reported
physician diagnosis, or use of insulin and/or diabetes mellitus
medications, as previously described.23
Statistical Analysis
Statistical analysis was conducted using STATA 15.0 (College
Station, TX). To obtain a robust association, homocysteine was
examined as either tertiles or a dichotomous variable using a
current clinical reference value (Hcy>12 lmol/L), which is
approximately the 87th percentile in theMESA data at baseline.
Calcification outcomes (CAC, AVC,MAC, DTAC) were treated as
binary variables (0=Agatston score of 0 or 1=Agatston score>0)
in prevalence and incidence models. Prevalence and incidence
ratios were estimated using relative risk regression (log-link) for
associations between homocysteine and calcification out-
comes with adjustments for age, race/ethnicity, sex, educa-
tion, clinic site, body mass index, hypertension, diabetes
mellitus, cigarette smoking, total cholesterol, HDL-C, creati-
nine-based estimated glomerular filtration rate (eGFRcr), statin
use, and CRP. CAC or DTAC progression was evaluated as the
change frombaselinemeasure to the last examinationwith CAC
or DTAC scans, normalized with the follow-up time (years).
Progression status for CAC was categorized into 3 groups: no
progression (defined asDCAC ≤0/year), moderate progression
(defined as 100>DCAC>0/year) and severe progression (de-
fined as DCAC ≥100/year). Progression of DTAC was catego-
rized in the same manner as CAC. Association between CAC/
DTAC progression and homocysteine was evaluated using
multinomial logistic regression adjusted for the same covari-
ates previously described.
Results
Demographic, lifestyle, and clinical characteristics of 6789
MESA participants were evaluated by the clinical homocys-
teine cutoff of Hcy>12 lmol/L (Table 1) and by homocys-
teine tertiles (Table 2). Individuals with higher homocysteine
levels were more likely to be older, men, less educated, taking
hypertension or lipid-lowering medications, to have elevated
systolic blood pressure, lower estimated glomerular filtration
rate, diabetes mellitus, elevated total cholesterol and HDL,
and increased prevalence of CAC, AVC, MAC, and DTAC.
Homocysteine-related prevalence and incidence ratios for
prevalent and incident calcification, respectively, are reported in
Table 3, adjusted for age, race, sex, education, clinic site, body
mass index, hypertension, diabetes mellitus, cigarette smoking,
total cholesterol, HDL-C, eGFRcr, statin use, and CRP. Homocys-
teine levels above the clinical cut-off of 12 lmol/L were
associated with prevalent CAC (prevalence ratio= 1.07, 95% CI
1.02–1.12), as were homocysteine levels in the second and third
tertiles (prevalence ratio=1.08, 95% CI 1.02–1.15 and preva-
lence ratio=1.11, 95% CI 1.05–1.17 respectively). Elevated
Table 1. Demographic, Lifestyle, and Clinical Characteristics
of 6789 MESA Participants Stratified by a Clinical
Homocysteine Cutoff Level of 12.0 lmol/L
Variable Hcy≤12 (n=5889) Hcy>12 (n=900)
Age, mean (SD) 61.4 (10.0) 67.0 (10.2)
Sex, n (% women) 3260 (55.4) 326 (36.2)
Education: highest level, n (%)
<High school 1004 (17.1) 218 (24.2)
Completed high school/GED 1048 (17.9) 182 (20.2)
Some college, <4 y degree 1710 (29.1) 217 (24.1)
Bachelor’s degree 1023 (17.4) 146 (16.2)
Graduate or
professional school
1082 (18.4) 136 (15.1)
Race, n (%)
White 2287 (38.8) 326 (36.2)
Chinese 704 (12.0) 98 (10.9)
Black 1591 (27.0) 289 (32.1)
Hispanic 1307 (22.2) 187 (20.8)
Cigarette smoking status, n (%)
Former 2148 (36.6) 332 (36.9)
Current 741 (12.6) 140 (15.6)
Alcohol intake, n (%)
Former 1361 (23.3) 256 (28.6)
Current 3272 (56.0) 465 (51.9)
BMI (kg/m2), mean (SD) 28.3 (5.5) 28.4 (5.4)
Systolic blood pressure
(mm Hg), mean (SD)
125.7 (21.0) 132.4 (23.3)
Hypertension medication, n (%) 2033 (34.5) 489 (54.3)
GFR (mL/min), mean (SD) 82.8 (16.7) 70.8 (25.0)
CRP (mg/L), median (Q1, Q3) 1.9 (0.8, 4.3) 2.0 (0.8, 4.2)
Diabetes mellitus, n (%) 703 (11.9) 161 (17.9)
Lipid-lowering medication, n (%) 905 (15.4) 189 (21.0)
Total cholesterol
(mg/dL), mean (SD)
194.8 (35.3) 189.6 (38.0)
HDL-C (mg/dL), mean (SD) 51.3 (14.8) 49.1 (14.7)
Prevalent CAC, n (%) 2779 (47.2) 607 (67.4)
Prevalent AVC, n (%) 701 (11.9) 209 (23.2)
Prevalent MAC, n (%) 491 (8.3) 149 (16.6)
Prevalent DTAC, n (%) 1481 (25.1) 364 (40.5)
AVC indicates aortic valve calcification; BMI, body mass index; CAC, coronary artery
calcification; CRP, C-reactive protein; DTAC, descending thoracic aorta calcification.;
GED, General Education Development test; GFR, glomerular filtration rate; Hcy,
Homocysteine; HDL-C, high-density lipoprotein cholesterol; MAC, mitral annular
calcification; MESA, Multi-Ethnic Study of Atherosclerosis.
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homocysteine above the clinical cut-off was also associated with
incident CAC (RR=1.21, 95% CI 1.04–1.40) and incident DTAC
(RR=1.29, 95%CI 1.01–1.64), but noassociationswere observed
across tertiles. Additionally, homocysteine levels in the third
tertile was significantly associated with prevalent mitral annular
calcification (RR=1.43, 95% CI 1.12–1.82). Homocysteine-
related odds ratios are reported in Table 4 for moderate
(100>DCAC or DDTAC >0/year) and severe (DCAC or DDTAC
≥100/year) progression of calcification for CAC and DTAC,
compared with no progression (DCAC or DDTAC ≤0/year).
Elevated homocysteine was found to be significantly associated
with moderate progression of CAC when evaluated using the
Table 2. Demographic, Lifestyle, and Clinical Characteristics of 6789 MESA Participants Stratified by Tertiles of Homocysteine
Variable
Homocysteine Tertile
1 2 3
Hcy, lmol/L (range) 3.2 to 7.7 7.8 to 9.8 9.9 to 118
Age, mean (SD) 58.5 (9.4) 62.3 (9.9) 65.7 (10.1)
Sex, n (% women) 1590 (69.9) 1122 (48.8) 874 (39.5)
Education: highest level, n (%)
<High school 401 (17.7) 366 (16.0) 455 (20.6)
Completed high school/GED 398 (17.5) 422 (18.4) 410 (18.6)
Some college, <4-y degree 661 (29.1) 638 (27.9) 628 (28.5)
Bachelor’s degree 400 (17.6) 403 (17.6) 366 (16.6)
Graduate or professional school 410 (18.1) 462 (20.2) 346 (15.7)
Race, n (%)
White 835 (36.7) 938 (40.8) 840 (38.0)
Chinese 323 (14.2) 252 (11.0) 227 (10.3)
Black 560 (24.6) 619 (26.9) 701 (31.7)
Hispanic 558 (24.5) 492 (21.4) 444 (20.1)
Cigarette smoking status, n (%)
Former 745 (32.8) 855 (37.3) 880 (39.9)
Current 269 (11.9) 298 (13.0) 314 (14.2)
Alcohol intake, n (%)
Former 512 (22.7) 527 (23.1) 578 (26.3)
Current 1225 (54.3) 1329 (58.2) 1183 (53.8)
BMI (kg/m2), mean (SD) 28.0 (5.7) 28.5 (5.3) 28.5 (5.4)
Systolic blood pressure (mm Hg), mean (SD) 122.5 (20.6) 126.7 (21.1) 130.7 (22.0)
Hypertension medication, n (%) 616 (27.1) 839 (36.5) 1067 (48.3)
GFR (mL/min), mean (SD) 88.0 (16.5) 81.4 (15.5) 74.0 (20.5)
CRP (mg/L), median (Q1, Q3) 1.9 (0.8, 4.5) 1.9 (0.8, 4.3) 1.9 (0.8, 4.1)
Diabetes mellitus, n (%) 254 (11.2) 264 (11.5) 346 (15.6)
Lipid-lowering medication, n (%) 321 (14.1) 358 (15.6) 415 (18.8)
Total cholesterol (mg/dL), mean (SD) 195.5 (34.5) 195.2 (35.9) 191.6 (36.7)
HDL-C (mg/dL), mean (SD) 52.9 (15.1) 50.7 (14.7) 49.3 (14.4)
Prevalent CAC, n (%) 837 (36.8) 1172 (50.9) 1377 (62.3)
Prevalent AVC, n (%) 184 (8.1) 267 (11.6) 459 (20.8)
Prevalent MAC, n (%) 128 (5.6) 202 (8.8) 310 (14.0)
Prevalent DTAC, n (%) 424 (18.6) 634 (27.6) 787 (35.6)
AVC indicates aortic valve calcification; BMI, body mass index; CAC, coronary artery calcification; CRP, C-reactive protein; DTAC, descending thoracic aorta calcification; GED, General
Education Development test; GFR, glomerular filtration rate; Hcy, Homocysteine; HDL-C, high-density lipoprotein cholesterol; MAC, mitral annular calcification; MESA, Multi-Ethnic Study of
Atherosclerosis.
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clinical cut-off (odds ratio [OR]=1.43, 95% CI 1.16–1.75) and for
the third tertile of homocysteine levels (OR=1.26, 95% CI 1.07–
1.48). Similarly, for severe progression of CAC, there was a
greater than 2-fold increased odds associated with elevated
homocysteine above the clinical cut-off (OR=2.21, 95% CI 1.60–
3.04) or within the third tertile (OR=2.18, 95% CI 1.53–3.10). For
DTAC, the association between homocysteine and moderate
DTAC progression was not statistically significant, but there was
a significant association between severe DTAC progression and
elevated homocysteine above the clinical cut-off (OR=1.42, 95%
CI 1.06–1.92), as well as for the second (OR=1.64, 95% CI 1.20–
2.24) and third tertiles (OR=1.63, 95% CI 1.16–2.27).
Discussion
In this multi-ethnic cohort of black, white, Chinese, and Hispanic
participants, homocysteine was significantly associated with
prevalence, incidence, and progression of CAC and DTAC. To
our knowledge, this is the first study to demonstrate an
association between elevated homocysteine and incidence
and progression of coronary and extra-coronary calcification.
Additionally, null findings were largely observed in analyses
of valvular calcification, suggesting that the influence of
homocysteine on calcification is restricted to vessels rather
than valves.
It has been previously established that CAC and DTAC are
tightly linked and share similar risk factor profiles for progres-
sion in the MESA cohort.20,22,24 Thus, our finding of significant
associations between elevated homocysteine and both types of
vascular calcification is consistent with prior studies on MESA
participants, indicating that the pathophysiological processes
driving CAC and DTAC are similar. These findings have been
reproduced in other cohorts as well; a recent analysis of CAC
and TAC in the Heinz Nixdorf Recall study found that the main
Table 3. Homocysteine-Related Prevalence and Incidence Ratios for Calcification Outcomes Among Participants of the MESA*
Calcification Outcome
Hcy Tertile Hcy
1 2 3 >12 lmol/L
Prevalent†
Coronary artery calcium ref 1.08
(1.02–1.15)
0.007‡
1.11
(1.05–1.17)
<0.001‡
1.07
(1.02–1.12)
0.003‡
Aortic valve calcification ref 0.92
(0.77–1.11)
0.39
1.15
(0.96–1.38)
0.14
1.13
(0.97–1.32)
0.12
Mitral annular calcification ref 1.14
(0.89–1.47)
0.31
1.43
(1.12–1.82)
0.004‡
1.18
(0.97–1.43)
0.09
Descending thoracic aortic calcification ref 1.09
(1.00–1.19)
0.04‡
1.07
(0.98–1.17)
0.16
1.02
(0.95–1.10)
0.57
Incident§
Coronary artery calcium ref 1.00
(0.89–1.12)
0.98
1.05
(0.93–1.19)
0.44
1.21
(1.04–1.40)
0.01‡
Aortic valve calcification ref 1.15
(0.66–1.99)
0.62
1.03
(0.56–1.88)
0.94
1.07
(0.62–1.85)
0.80
Mitral annular calcification ref 0.94
(0.56–1.56)
0.81
0.90
(0.51–1.61)
0.73
1.21
(0.60–2.43)
0.60
Descending thoracic aortic calcification ref 0.93
(0.71–1.21)
0.57
1.00
(0.75–1.32)
0.98
1.29
(1.01–1.64)
0.04‡
Hcy indicates homocysteine; MESA, Multi-Ethnic Study of Atherosclerosis; ref, reference group.
*Relative risk regression (log-link) adjusted for age, race, sex, education, clinic site, body mass index, hypertension, diabetes mellitus, cigarette smoking, total cholesterol, high-density
lipoprotein cholesterol, creatinine-based estimated glomerular filtration rate (eGFRcr), statin use, and C-reactive protein. Individuals with missing covariate data were excluded (n=70 for
prevalent-case analysis, and n=32 for incident-case analysis).
†Data shown are prevalence ratios, 95% CIs and P values.
‡Data with significant P values.
§Data shown are incidence ratios, 95% CIs and P values.
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determinants for CAC and TAC incidence and progression were
predominantly the same.25
In contrast to vascular calcification, the associations
between homocysteine and valvular calcification were largely
non-significant, indicating that the pathophysiologic mecha-
nism for valvular calcification differs from that of vascular
calcification as had been reported previously.26,27 Specifically,
a recent study using positron emission tomography and CT to
measure active calcification and inflammation in the aortic
valve, aorta and coronary arteries found that active inflam-
mation was more pronounced in areas of vascular calcification
than in calcific valves.26
While elevated homocysteine has been previously associ-
ated with prevalent coronary calcification, no study has
demonstrated an association between incident coronary
calcification and elevated homocysteine. Additionally, there
has been only 1 small study (n=133) demonstrating a
significant association between elevated homocysteine and
coronary artery calcification progression.28 However, this prior
study did not show an association between elevated homo-
cysteine and CAC prevalence or incidence, nor did it assess
extra-coronary calcification. Therefore, to our knowledge, our
study is the first to demonstrate significant associations
between homocysteine and prevalence, incidence and pro-
gression of both coronary and extra-coronary calcification.
Prior in vitro studies provide mechanistic support for the
associations observed in the present study, with several
studies demonstrating an association between homocysteine,
inflammation, and calcification.2,29,30 Specifically, in vitro
studies have demonstrated that elevated homocysteine
increases reactive oxygen species production in microvascular
endothelial cells, leading to induction of inflammatory
responses mediated by nuclear factor-jB.2,31 Additionally,
homocysteine has been shown to promote osteogenic differ-
entiation and calcium deposition in vitro, and homocysteine
was found at higher levels in calcified human atheroma, when
compared with non-calcified biopsies.29 Therefore, we hypoth-
esize that elevated homocysteine is a contributor to this
pathophysiologic process of vascular inflammation and dam-
age that leads to vascular calcification but does not play a
significant role in valvular calcification.
There is currently considerable debate in the literature as
to whether homocysteine is a causal risk factor for CHD, a
risk marker for CHD, or neither. A recent Cochrane systematic
review assessed 15 randomized controlled trials and con-
cluded that they demonstrate no effects of homocysteine-
lowering interventions on myocardial infarction, adverse
events, or mortality.32 Additionally, a 2012 meta-analysis of
19 unpublished data sets found that genetic variants in the
methylene tetrahydrofolate reductase gene (MTHFR) associ-
ated with moderate hyperhomocysteinemia were not associ-
ated with an increased risk for CHD.10 The investigators
Table 4. Homocysteine-Related Odds Ratios for Moderate-to-Severe Progression of Calcification in Coronary Arteries and the
Descending Thoracic Aorta*†
Calcification Progression
Homocysteine Tertile Hcy
1 2 3 >12 lmol/L
CAC progression rate‡§
100>DCAC >0/y ref 1.13
(0.98–1.30)
0.10
1.26
(1.07–1.48)
0.007k
1.43
(1.16–1.75)
<0.001k
DCAC ≥100/y ref 1.33
(0.94–1.89)
0.11
2.18
(1.53–3.10)
<0.001k
2.21
(1.60–3.04)
<0.001k
DTAC progression rate§¶
100>DDTAC >0/y ref 1.04
(0.87–1.26)
0.66
1.05
(0.86–1.29)
0.63
1.19
(0.96–1.47)
0.12
DDTAC ≥100/y ref 1.64
(1.20–2.24)
0.002k
1.63
(1.16–2.27)
0.004k
1.42
(1.06–1.92)
0.02k
CAC indicates coronary artery calcification; DTAC, descending thoracic aorta calcification; Hcy, homocysteine; ref, reference group.
*Multinomial logistic regression adjusted for age, race, sex, education, clinic site, body mass index, hypertension, diabetes mellitus, cigarette smoking, total cholesterol, high-density
lipoprotein cholesterol, creatinine-based estimated glomerular filtration rate (eGFRcr), statin use, and C-reactive protein. Individuals with missing covariate data were excluded (n=61).
†Respective analyses include participants with baseline measurements and at least 1 follow-up measurement of CAC (n=5992) and DTAC (n=5811).
‡CAC progression rate, cases: 100>DCAC >0/year (3366 cases) or DCAC >100/year (408 cases).
§Data shown are odds ratios, 95% CIs and P values.
kData with significant P values.
¶DTAC progression rate, cases: 100>DDTAC >0/year (1171 cases) or DDTAC >100/year (444 cases).
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concluded that the discrepancy between their null findings
and prior studies demonstrating an association between
homocysteine and CHD should be attributed to publication
bias of prior studies because of positivity of results and/or
methodologic issues with those earlier studies.10 Given these
recent publications, interest in homocysteine as a cardiovas-
cular biomarker has diminished. However, the randomized
controlled trials and meta-analysis have some important
limitations that may have influenced their findings. First, the
majority of randomized controlled trials using homocysteine-
lowering interventions had short treatment and follow-up
periods (≤2 years).32,33 The longest randomized controlled
trial, WAFACS (Women’s Antioxidant and Folic Acid Cardio-
vascular Study), had a follow-up period of 7.3 years and only
measured homocysteine directly in 5% of participants, and
therefore could not directly identify participants with high
homocysteine levels to determine whether this subgroup had
a significant reduction in cardiovascular events from homo-
cysteine-lowering vitamin regimens.33 It is additionally impor-
tant to note that WAFACS enrolled only high-risk women with
known cardiovascular disease or at least 3 cardiovascular risk
factors.33 Therefore, this study likely had a high percentage of
subjects with established coronary artery and/or thoracic
aorta calcification. Calcification is not reversible, and there-
fore if homocysteine contributes to risk for vascular calcifi-
cation, reduction of homocysteine would not be expected to
impact outcomes in a high-risk cohort likely to already have
established vascular calcification. Additionally, prior studies
have demonstrated that, while homocysteine levels are
influenced by both genetic and environmental factors, levels
in an individual are relatively constant over time.34,35
Therefore, it is possible that short-term reduction in homo-
cysteine levels through B vitamin supplementation is not
sufficient to reverse or impact the cardiovascular effects of
lifelong, chronic elevation of homocysteine. Relatedly, the
2012 meta-analysis that found no association between
hyperhomocysteinemia-associated MTHFR variants and CHD
also did not have directly measured homocysteine levels for
participants. Therefore the meta-analysis data support the
conclusion that MTHFR variants are not associated with CHD,
but are not sufficient to discount the impact of elevated
homocysteine on cardiovascular outcomes.10 In fact, a 2009
study assessed the association of MTHFR variants with
homocysteine levels in the Coronary Artery Risk Development
in Young Adults cohort, both before and after folate fortifi-
cation was implemented in the United States in 1998, and
found that MTHFR variants in the post-fortification era were
neither required nor sufficient to cause hyperhomocysteine-
mia.36 Relatedly, it is important to note that the MESA study
occurred in the era of folate fortification, and yet 900 of 6789
MESA subjects had homocysteine levels above the clinical
cut-off, with those elevated levels associated with vascular
calcification in our study.
Our study does have some limitations. While CAC was
assessed at multiple follow-up visits, the remaining calcifica-
tion measures (DTAC, AVC, MAC) were assessed at only a
single follow-up visit. Therefore, the weaker associations of
elevated homocysteine with prevalent and incident DTAC and
DTAC progression may be attributable to the longer follow-up
period for CAC. Assessing visit 4 and 5 scans for DTAC
progression would determine whether a longer follow-up period
strengthens associations between elevated homocysteine and
DTAC incidence and progression. An additional limitation of the
study is that homocysteine was measured at the baseline visit
only, and not measured at follow-up visits in parallel with
calcification assessments. However, as stated previously, prior
studies have demonstrated relative stability of homocysteine
over time and therefore lack of repeat homocysteine measure-
ments is unlikely to impact our results.34,35
Conclusions
This study confirms prior research demonstrating an associa-
tion between homocysteine and vascular calcification preva-
lence and demonstrates a new potential role for homocysteine
as a biomarker for both coronary and extra-coronary vascular
calcification incidence and progression. CAC and DTAC
progression have been shown to be associated with increased
risk for all-cause mortality, hard and total CHD events,37–39 and
therefore a biomarker that identifies risk for vascular calcifi-
cation progression would be a valuable tool for providers to
more accurately risk stratify their patients. While recent
literature has concluded that homocysteine is not associated
with increased risk for cardiovascular disease, these conclu-
sions may be premature, as the majority of these studies failed
to directly measure homocysteine in participants and instead
correlated MTHFR variants or B vitamin supplementation with
cardiovascular end points. Therefore, future research is needed
in large cohorts with direct homocysteine measurement, not
only to confirm our novel findings, but to further clarify the role
of homocysteine in cardiovascular disease.
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